Arcadia Biosciences Q2 Loss Widens to $6.27M; Going Concern and Nasdaq Delisting Risks Mount
RKDA is trading near its 52-week low of $0.497 (15% above the low) on light trading volume (0.2× avg).
Summary
Arcadia Biosciences reported a Q2 net loss of $6.27 million, reiterated going concern doubts, and disclosed material weaknesses and Nasdaq delisting risks.
Key Events · Earnings and Guidance · RKDA
-
Q2 Net Loss Widens to $6.27M
Net loss for Q2 2026 was $6.27 million, up from $4.4 million in Q1 2026, driven by a $5.4 million valuation loss on the June 2026 PIPE and $2.8 million unrealized loss on AFII common stock.
-
Going Concern Doubt Reiterated
With only $4.2 million in cash as of June 30, 2026, management states existing cash will not meet anticipated requirements for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
-
Material Weaknesses in Internal Controls
The company disclosed material weaknesses related to insufficient segregation of duties and insufficient information system controls, with disclosure controls and procedures deemed not effective.
-
Nasdaq Delisting Risks
The company received a minimum bid price deficiency notice on August 4, 2026, with a compliance deadline of February 1, 2027, and expects a minimum stockholders' equity deficiency notice after this filing. A new minimum MVLS rule could also trigger immediate delisting if effective.
Analysis · RKDA · Energy & Transportation
The 10-Q confirms a widening net loss of $6.27 million for Q2 2026, up from $4.4 million in Q1, driven by a $5.4 million valuation loss on the June 2026 PIPE and $2.8 million unrealized loss on AFII stock. Management reiterates substantial doubt about the company's ability to continue as a going concern, with only $4.2 million in cash against a 12-month cash requirement that cannot be met. The filing also discloses material weaknesses in internal controls and multiple Nasdaq delisting risks, including a minimum bid price deficiency and an expected minimum stockholders' equity deficiency. These factors collectively threaten the company's listing and access to capital, making this a critical update for investors.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 43.6% of the 289 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RKDA was trading at $0.57 on NASDAQ in the Energy & Transportation sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.50 to $6.71. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.